ClinicalTrials.gg
CompletedNCT00536731ESTHERUpdated Aug 15, 2012Results posted

Symbicort Rapihaler Therapeutic Equivalence Study

A Phase 3 interventional study of Symbicort Turbuhaler and Symbicort pMDI in Bronchial Asthma, sponsored by AstraZeneca. Completed at 50 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
742
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
19th of 108
742 · median 124
Started
2007
with 11 others
Phase 3
51 of 110
3 open now
Registered
31st of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 19th largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 51 in phase 3, and was the 31st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Asthma
  • Symbicort
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma clinically diagnosed since at least 6 months.
  • Lung function values measured ≥ 50% and ≤ 90% of predicted normal.
  • Patients with reversible airway obstruction Daily use of inhaled (any brand) for >3 months.

Exclusion criteria

Exclusion Criteria:

  • Use of oral, rectal or parenteral within 30 days prior to start of study.
  • Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to start of randomised treatment.
  • Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
742 participants (actual)

Study arms

  • Active comparator
    Symbicort pMDI

    Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily

    Drug: Symbicort pMDI

  • Active comparator
    Symbicort Turbuhaler

    Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily

    Drug: Symbicort Turbuhaler

  • Active comparator
    Pulmicort Turbuhaler

    Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily

    Drug: Pulmicort Turbuhaler

Interventions

  • Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily

  • DrugSymbicort pMDI

    Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily

  • Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily

06

What researchers measure

Primary outcomes

  1. Morning Peak Expiratory Flow (PEF)

    Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Evening Peak Expiratory Flow (PEF)

    Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed

    Time frame: Baseline to 6 weeks

  2. Asthma Symptom Score, Night

    Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

    Time frame: Baseline to 6 weeks

  3. Asthma Symptom Score, Day

    Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

    Time frame: Baseline to 6 weeks

  4. Asthma Symptom Score, Total

    Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

    Time frame: Baseline to 6 weeks

  5. Percentage of Nights With Awakenings Due to Asthma

    Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered "Yes" or "No" whether she/he woke up during the night due to asthma.

    Time frame: Baseline and 6 weeks

  6. Use of Rescue Medication, Night

    Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

    Time frame: Baseline to 6 weeks

  7. Use of Rescue Medication, Day

    Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

    Time frame: Baseline to 6 weeks

  8. Use of Rescue Medication, Total

    Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

    Time frame: Baseline to 6 weeks

  9. Percentage of Symptom-free Days

    Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.

    Time frame: Baseline to 6 weeks

  10. Percentage of Asthma Control Days

    Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.

    Time frame: Baseline to 6 weeks

  11. Percentage of Rescue Free Days

    Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.

    Time frame: Baseline to 6 weeks

  12. Forced Expiratory Volume in 1 Second (FEV1)

    Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)

    Time frame: Baseline to 6 weeks

07

Results

Posted Aug 15, 2012

Participant flow

898 subjects enrolled; 156 not randomised: 94 incorrect enrolment, 9 adverse events, 18 voluntary discontinuations, 1 lost to follow-up, 1use of not allowed medication, 1 non-compliant

Participant flow — Overall Study
MilestoneSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Started253246243
Completed249241238
Not completed455
Withdrew: Adverse event323
Withdrew: Withdrawal by subject020
Withdrew: Intake of prohibited conc. medication001
Withdrew: Safety reasons001
Withdrew: Other110

Outcome measures

PrimaryMorning Peak Expiratory Flow (PEF)

Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Liters/min
Morning Peak Expiratory Flow (PEF)
Liters/minSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Morning Peak Expiratory Flow (PEF)12.88 ± 24.613.78 ± 29.74.59 ± 27.9
SecondaryEvening Peak Expiratory Flow (PEF)

Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Liters/min
Evening Peak Expiratory Flow (PEF)
Liters/minSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Evening Peak Expiratory Flow (PEF)12.34 ± 24.310.80 ± 29.11.43 ± 25.7
SecondaryAsthma Symptom Score, Night

Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Units on a scale
Asthma Symptom Score, Night
Units on a scaleSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Asthma Symptom Score, Night-0.24 ± 0.41-0.27 ± 0.41-0.15 ± 0.39
SecondaryAsthma Symptom Score, Day

Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Units on a scale
Asthma Symptom Score, Day
Units on a scaleSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Asthma Symptom Score, Day-0.21 ± 0.38-0.24 ± 0.40-0.15 ± 0.40
SecondaryAsthma Symptom Score, Total

Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Units on a scale
Asthma Symptom Score, Total
Units on a scaleSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Asthma Symptom Score, Total-0.45 ± 0.73-0.51 ± 0.75-0.30 ± 0.73
SecondaryPercentage of Nights With Awakenings Due to Asthma

Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered "Yes" or "No" whether she/he woke up during the night due to asthma.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · Percentage of night
Percentage of Nights With Awakenings Due to Asthma
Percentage of nightSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Percentage of Nights With Awakenings Due to Asthma-14.0 ± 24.1-14.0 ± 26.4-8.3 ± 25.5
SecondaryUse of Rescue Medication, Night

Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Inhalations
Use of Rescue Medication, Night
InhalationsSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Use of Rescue Medication, Night-0.41 ± 0.64-0.39 ± 0.76-0.19 ± 0.67
SecondaryUse of Rescue Medication, Day

Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Inhalations
Use of Rescue Medication, Day
InhalationsSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Use of Rescue Medication, Day-0.21 ± 0.39-0.20 ± 0.47-0.13 ± 0.56
SecondaryUse of Rescue Medication, Total

Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Inhalations
Use of Rescue Medication, Total
InhalationsSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Use of Rescue Medication, Total-0.62 ± 0.89-0.58 ± 1.09-0.32 ± 1.12
SecondaryPercentage of Symptom-free Days

Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Percentage of days
Percentage of Symptom-free Days
Percentage of daysSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Percentage of Symptom-free Days12.5 ± 23.715.3 ± 24.59.1 ± 21.2
SecondaryPercentage of Asthma Control Days

Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Percentage of days
Percentage of Asthma Control Days
Percentage of daysSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Percentage of Asthma Control Days12.7 ± 23.615.1 ± 24.49.1 ± 21.2
SecondaryPercentage of Rescue Free Days

Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Percentage of days
Percentage of Rescue Free Days
Percentage of daysSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Percentage of Rescue Free Days24.0 ± 30.926.2 ± 30.717.2 ± 28.4
SecondaryForced Expiratory Volume in 1 Second (FEV1)

Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)

Time frame:
Baseline to 6 weeks
Reported as:
Mean · Liters
Forced Expiratory Volume in 1 Second (FEV1)
LitersSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
Forced Expiratory Volume in 1 Second (FEV1)0.095 ± 0.3280.147 ± 0.3640.112 ± 0.326

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort pMDI—0/253 (0%)0/253 (0%)
Symbicort Turbuhaler—1/246 (0.4%)0/246 (0%)
Pulmicort Turbuhaler—1/243 (0.4%)0/243 (0%)
Most frequent serious events
Most frequent serious events
EventSymbicort pMDISymbicort TurbuhalerPulmicort Turbuhaler
AsthmaRespiratory, thoracic and mediastinal disorders0/2531/2461/243

Baseline characteristics

Age Continuous
Age Continuous(years)Symbicort pMDISymbicort TurbuhalerPulmicort TurbuhalerTotal
Mean41 (12 to 75)42 (12 to 76)39 (12 to 78)41 (12 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort pMDISymbicort TurbuhalerPulmicort TurbuhalerTotal
Female152142131425
Male101104112317
08

Study locations

50 sites
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Rousse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Benesov U Prahy, Czech Republic
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Jihlava, Czech Republic
  • Research Site
    Kladno, Czech Republic
  • Research Site
    Kolin, Czech Republic
  • Research Site
    Kutna Hora, Czech Republic
  • Research Site
    Litomerice, Czech Republic
  • Research Site
    Neratovice, Czech Republic
  • Research Site
    Pardubice, Czech Republic
  • Research Site
    Praha 4, Czech Republic
  • Research Site
    Praha 5, Czech Republic
  • Research Site
    Praha 8, Czech Republic
  • Research Site
    Rokycany, Czech Republic
  • Research Site
    Strakonice, Czech Republic
  • Research Site
    Balassagyarmat, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Cegléd, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Deszk, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Gyula, Hungary
  • Research Site
    Kaposvar, Hungary
  • Research Site
    Nyíregyháza, Hungary
  • Research Site
    Szarvas, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Százhalombatta, Hungary
  • Research Site
    Törökbálint, Hungary
  • Research Site
    Bialystok, Poland
  • Research Site
    Bielsko-biala, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Chodziez, Poland
  • Research Site
    Chrzanow, Poland
  • Research Site
    Karpacz, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Lomza, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Ostrow Wielkopolski, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Skierniewice, Poland
  • Research Site
    Szczecin, Poland
  • Research Site
    Tarnow, Poland
  • Research Site
    Turek, Poland
  • Research Site
    Wodzislaw Slaski, Poland
  • Research Site
    Wroclaw, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Sep 28, 2007
Start
Sep 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Aug 15, 2012
Last update
Aug 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00536731
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 28, 2007
Start date
Sep 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Aug 15, 2012
Last update
Aug 15, 2012

Study contacts

Tomas Andersson
study director · AstraZeneca
Akos Somoskovi
principal investigator · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol · Budesonide

Start the discussion